Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 931 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Orthomyxoviridae Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT05874713
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

NCT02213354
View directory record Official record
Conditions
Avian Influenza
Interventions
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 17, 2026, 9:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.

NCT01262079
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression

NCT01733056
View directory record Official record
Conditions
Immunosuppression
Interventions
Flu Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 17, 2026, 9:02 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

High-Dose Influenza Vaccine in Nursing Homes

NCT01815268
View directory record Official record
Conditions
Influenza
Interventions
HD Vaccine, SD Vaccine, Free Vaccine, Usual Care
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
3
States / cities
Cleveland, Ohio • Providence, Rhode Island • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

NCT02251288
View directory record Official record
Conditions
Avian Influenza, Immunisation
Interventions
Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 47 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of a Flu Vaccine in Children

NCT00001127
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (CAIV-T)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 18 Years
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

NCT03300050
View directory record Official record
Conditions
Influenza, Vaccine
Interventions
cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 17, 2026, 9:02 AM EDT
Recruiting No phase listed Observational

COVID-19 Coagulopathy Extension Study

NCT05334615
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Flu Vaccine Doses in Children

NCT01164553
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 35 Months
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Not applicable Interventional

Adult Influenza Vaccination Text Message Reminders

NCT01942824
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Text Messages
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 17, 2026, 9:02 AM EDT
Withdrawn Phase 2 Interventional

High Dose Influenza in Immunosuppressed Subjects

NCT00766285
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

NCT02545543
View directory record Official record
Conditions
Influenza, Human
Interventions
Seqirus QIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
5 Years to 17 Years
Enrollment
2,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
32
States / cities
Huntsville, Alabama • Madera, California • Ontario, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Not applicable Interventional Results available

PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging

NCT01974050
View directory record Official record
Conditions
Pregnancy
Interventions
Text message surveillance
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

NCT01573312
View directory record Official record
Conditions
Influenza
Interventions
ASO3 Adjuvant, Influenza A/H5N1 Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 4 Interventional Results available

A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

NCT00412737
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 4 Interventional Results available

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women

NCT02783170
View directory record Official record
Conditions
Pregnancy
Interventions
Tetanus, Diphtheria, and Pertussis Vaccine, 2016-2017 Quadrivalent Inactivated Influenza Vaccine, 2017-2018 Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 17, 2026, 9:02 AM EDT
Completed No phase listed Observational

Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B

NCT01753531
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu Symptoms
Device
Lead sponsor
Sekisui Diagnostics, LLC
Industry
Eligibility
3 Months and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Charleston, South Carolina • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 17, 2026, 9:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study for Collection of Anti-Influenza A Immune Plasma

NCT00984451
View directory record Official record
Conditions
Influenza A Virus Infection, Swine Flu
Interventions
Plasma collection following infection or vaccination with influenza A
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 17, 2026, 9:02 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Xofluza-Wearables Feasibility-Study

NCT06161454
View directory record Official record
Conditions
Infection, Coronavirus, Infections, Influenza, Transplant, Infection Viral
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
498 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 17, 2026, 9:02 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

NCT01224795
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo Comparator
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
96
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers

NCT02183753
View directory record Official record
Conditions
Response of Viral Infection to Woodsmoke
Interventions
wood smoke, clean air
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01859143
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 17, 2026, 9:02 AM EDT